glp 1 agonist vs analog Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Frontiers | GLP-1 receptor agonist
Description
Results from Eli Lilly's Phase III study for the GLP-1 are being presented at the ADA's 85th Scientific Sessions in June and additionally published in a journal
Perspective on the Rx Pipeline: Diabetes and GLP-1 Agonists Situation Summary Initial therapy for individuals with T2DM who are at high risk for CVD, heart failure (HF) and/or chronic kidney disease is metformin and a glucagon-like peptide 1 (GLP-1) or sodium glucose transporter ligand 2 (SGLT-2)
Alli is only approved for use in adults aged 18 and older
N Engl J Med 2023;389:22212232
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al
